NextCure (NXTC) News Today $0.45 -0.01 (-2.17%) Closing price 06/27/2025 04:00 PM EasternExtended Trading$0.44 -0.01 (-2.89%) As of 06/27/2025 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock NXTC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period NextCure shareholders approve board elections and reverse stock split proposalJune 25, 2025 | uk.investing.comNextCure shareholders approve board elections and reverse stock split proposal - Investing.comJune 25, 2025 | investing.comNextCure Inks $745M Deal With Simcere For Cancer Drug: Retail’s More Optimistic Despite Stock’s 27% DeclineJune 16, 2025 | msn.comNextCure signs up to $745 million deal with China's Simcere to develop cancer drugJune 16, 2025 | reuters.comNextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6June 16, 2025 | globenewswire.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ...May 30, 2025 | morningstar.comMNextCure, Inc. and LigaChem Biosciences Announce Phase 1 Study of LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, to be Presented at ASCO 2025May 30, 2025 | nasdaq.comNextCure, Inc. (NXTC) and LCB to Unveil Promising Preclinical Data on B7-H4 ADC at AACR 2024May 29, 2025 | insidermonkey.comNextCure and LigaChemBio to Present Trial in Progress Poster for LNCB74, a B7-H4 Targeted Antibody-Drug Conjugate, as Monotherapy in Participants with Advanced Solid Tumors at ASCO 2025May 29, 2025 | globenewswire.comNextCure Provides Business Update and Reports First Quarter 2025 Financial ResultsMay 1, 2025 | globenewswire.comNextCure to Present at 24th Annual Needham Virtual Healthcare ConferenceApril 4, 2025 | globenewswire.comH.C. Wainwright says competitor data builds optimism for NextCure’s LNCB74March 17, 2025 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for NextCure (NXTC)March 8, 2025 | markets.businessinsider.comNextCure Reports 2024 Financials and Strategic ProgressMarch 7, 2025 | tipranks.comNextCure, Inc. Completes First Cohort of Phase 1 Trial for LNCB74 and Plans for Backfill CohortsMarch 6, 2025 | quiverquant.comQNextCure Provides Business Update and Reports Full Year 2024 Financial ResultsMarch 6, 2025 | globenewswire.comNextCure stock plunges to 52-week low, hits $0.69February 12, 2025 | msn.comNextCure Announces First Patient Dosed in the Phase 1 Study of LNCB74 (B7-H4 ADC) as Therapeutic for Treating Multiple CancersJanuary 10, 2025 | globenewswire.comNextCure stock hits 52-week low at $0.99 amid market challengesDecember 18, 2024 | investing.comNextCure Announces Acceptance of IND Application for LNCB74December 10, 2024 | globenewswire.comNextCure to Participate in the 36th Annual Piper Sandler Healthcare ConferenceNovember 26, 2024 | globenewswire.comPreclinical Data Demonstrates Anti-Siglec-15 Treatment Enhanced Generation of Quality Bone with Better Mechanical Properties in Mice with Moderate-to-Severe Osteogenesis ImperfectaNovember 19, 2024 | globenewswire.comNextCure Reports Improved Financial Performance and Strategic FocusNovember 12, 2024 | markets.businessinsider.comNextCure’s Strategic Shift and Financial Stability Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comNextCure Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 7, 2024 | globenewswire.comNextCure reports data from LNCB74, NC410 studiesNovember 7, 2024 | markets.businessinsider.comNextCure (NXTC) Earnings Dates & ReportsNovember 5, 2024 | investing.comNextCure Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo at Society for Immunotherapy of Cancer Annual MeetingNovember 5, 2024 | globenewswire.comNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | markets.businessinsider.comNextCure to Give Two Presentations at Society for Immunotherapy of Cancer Annual MeetingOctober 4, 2024 | globenewswire.comNextCure Presented Results of the Phase 1b Study of NC410 in Combination with Pembrolizumab at ESMO 2024September 16, 2024 | globenewswire.comIs NextCure (NASDAQ:NXTC) In A Good Position To Deliver On Growth Plans?September 3, 2024 | finance.yahoo.comBuy Rating for NextCure Supported by Promising Clinical Results and Strong Financial PositionAugust 3, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on NextCure (NXTC)August 3, 2024 | markets.businessinsider.comNextCure Provides Business Update and Reports Second Quarter 2024 Financial ResultsAugust 1, 2024 | stockhouse.comNextCure to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceJune 20, 2024 | globenewswire.comNextCure Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024May 30, 2024 | globenewswire.comNextCure, Inc. (NXTC)May 29, 2024 | finance.yahoo.comBuy Rating Affirmed for NextCure Amid Promising Oncology Treatment Prospects and Solid FinancialsMay 4, 2024 | markets.businessinsider.comNXTC Stock Earnings: NextCure Misses EPS for Q1 2024May 2, 2024 | investorplace.comNextCure Provides Business Update and Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comNextCure to Present Phase 1b Data of NC410 in Combination with Pembrolizumab at ASCO 2024April 24, 2024 | globenewswire.comPromising Clinical Outlook for NextCure’s Novel ADC LNCB74 Spurs Buy RatingApril 8, 2024 | markets.businessinsider.comNextCure and LCB Present Preclinical Data on B7-H4 Antibody Drug Conjugate at AACR 2024April 8, 2024 | globenewswire.comNextCure Appoints Dr. Rakesh Dixit to Scientific Advisory BoardApril 4, 2024 | globenewswire.comNextCure to Present at 23rd Annual Needham Virtual Healthcare ConferenceApril 2, 2024 | globenewswire.comNextCure, Inc. (NASDAQ:NXTC) Short Interest UpdateMarch 27, 2024 | marketbeat.comWill NextCure (NASDAQ:NXTC) Spend Its Cash Wisely?March 27, 2024 | finance.yahoo.comWall Street's Favorite Penny Stocks? 7 Names That Could Make You Filthy RichMarch 23, 2024 | investorplace.comPromising Clinical Trial Results for NextCure’s NC410 Bolster Buy RatingMarch 22, 2024 | markets.businessinsider.com Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address NXTC Media Mentions By Week NXTC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NXTC News Sentiment▼0.620.93▲Average Medical News Sentiment NXTC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NXTC Articles This Week▼30▲NXTC Articles Average Week Get NextCure News Delivered to You Automatically Sign up to receive the latest news and ratings for NXTC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TELO News Today AADI News Today CNTX News Today ANVS News Today RNXT News Today AVTX News Today IPSC News Today KLTO News Today VTVT News Today BLUE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NXTC) was last updated on 6/30/2025 by MarketBeat.com Staff From Our PartnersIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredWhy Is President Trump Fast-Tracking These Companies?Forget about AI… There's a hot new trend on Wall Street… And it's all thanks to President Trump. His ...InvestorPlace | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | Sponsored“Trump’s 24-Hour Profit Windows” revealedTrading legend Larry Benedict has discovered a repeating surge of $240 billion (and more)... Flowing into a...Brownstone Research | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored379 passengers walked away from thisElon Musk just wrote a $51 million check to back this material’s next phase… Because it’s not just saving l...True Market Insiders | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NextCure, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share NextCure With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NXTC Stock Alerts